<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01578005</url>
  </required_header>
  <id_info>
    <org_study_id>10 047 08</org_study_id>
    <secondary_id>2010-A00471-38</secondary_id>
    <nct_id>NCT01578005</nct_id>
  </id_info>
  <brief_title>IVUS Assessment of Atheroma Burden After Acute Coronary Syndrome</brief_title>
  <acronym>OPTIVUS</acronym>
  <official_title>Intravascular Ultrasound (IVUS) Assessment of the Atherosclerotic Plaque Causing an Acute Coronary Syndrome: One-year Changes Under Optimal Secondary Prevention Drug Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary angioplasty is rather frequently performed in such situations, presumably because,
      changes in the atherosclerotic plaque under drug treatment, have remained poorly described so
      far. Intravascular ultrasound (IVUS) enables a precise description of coronary atheroma,
      better than the one provided by coronary angiography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to current guidelines, patients with coronary lesions with stenosis &lt;70% should
      receive optimal secondary prevention drug treatment without angioplasty, even after an acute
      coronary syndrome (ACS). Nevertheless, coronary angioplasty is rather frequently performed in
      such situations, presumably because, changes in the atherosclerotic plaque under drug
      treatment, have remained poorly described so far. Intravascular ultrasound (IVUS) enables a
      precise description of coronary atheroma, better than the one provided by coronary
      angiography.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>atheroma volume</measure>
    <time_frame>one year</time_frame>
    <description>One-year changes in percent atheroma volume (PAV), total atheroma volume (TAV) and normalized TAV, measured in the lesion which has promoted the ACS (unstable plaque).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PAV</measure>
    <time_frame>1 year</time_frame>
    <description>One-year changes in PAV, TAV and normalized TAV, in a stable plaque (not involved in the ACS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of the clinical cardiovascular events</measure>
    <time_frame>1 year</time_frame>
    <description>one year incidence of clinical cardiovascular events (death, acute coronary syndrome, ischaemic stroke, revascularization, hospitalization for heart failure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TAV</measure>
    <time_frame>1 year</time_frame>
    <description>One-year changes in PAV, TAV and normalized TAV, in a stable plaque (not involved in the ACS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>normalized TAV</measure>
    <time_frame>1 year</time_frame>
    <description>One-year changes in PAV, TAV and normalized TAV, in a stable plaque (not involved in the ACS)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      bioanalysis on DNA, searching genes involving coronary disease
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        female and male aged more than 18 years hospitalized for acute coronary syndrom
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients hospitalized for ACS, for whom the target lesion has less than 70%
             stenosis and not treated with coronary angioplasty.

        Exclusion Criteria:

          -  Patients presenting with a target lesion with ≥70% stenosis ; Patients for whom the
             target lesion is treated with coronary angioplasty ; Interventions: A first IVUS will
             be performed after the acute coronary event (baseline) and will be done again one-year
             after to assess changes in the atherosclerotic plaques.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meyer Elbaz, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Coste, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrice Virot, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Limoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meyer ELBAZ, PhD</last_name>
    <phone>05 61 32 3316</phone>
    <phone_ext>+33</phone_ext>
    <email>elbaz.m@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UH Bordeaux Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <state>Bordeaux Pessac</state>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Coste, PhD</last_name>
      <phone>05.57.65.64.57</phone>
      <email>pierre.coste@u-bordeaux2.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Coste, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrice Virot, PhD</last_name>
      <phone>05.55.05.63.10</phone>
      <email>patrice.virot@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice Virot, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UH Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meyer Elbaz, PhD</last_name>
      <phone>05 61 32 33 16</phone>
      <phone_ext>+33</phone_ext>
      <email>elbaz.m@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Meyer Elbaz, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute coronary syndrome</keyword>
  <keyword>IVUS</keyword>
  <keyword>atherosclerotic plaque</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

